The In Silico Child: Using Simulation to Guide Pediatric Drug Development and Manage Pediatric Pharmacotherapy

摘要: Significant gains have been made in the appreciation of pediatrics as an important population which rationale pharmacotherapy guidance is warranted but often currently lacking. Although regulatory framework for major improvements pediatric drug development was implemented Europe a decade later than United States, recent efforts, including 2007 "Better Medicines Children" initiative, indicate that awareness this problem indeed global phenomenon. Nevertheless, there still remains gap between and implementation scientifically based applied children. Specifically, vision how best to move from empiricism toward plan incorporates biologic knowledge about maturation physiologic processes well drug- disease-specific generated adults must evolve present intentions. Modeling simulation approaches can facilitate such ultimately should provide benefit patients. examples silico are compelling, their ultimate value may be identification data studies better guide therapy education caregivers principles clinical pharmacology underlie optimal pharmacotherapeutic decisions